Literature DB >> 17718852

Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency.

J Drouin1, S Bilodeau, S Vallette.   

Abstract

The pituitary gland orchestrates our endocrine environment: it produces hormones in response to hypothalamic factors that integrate neural inputs and its activity is balanced by the feedback action of peripheral hormones. Disruption of this equilibrium has severe consequences that affect multiple systems and may be fatal. Genetic analysis of pituitary function led to discovery of critical transcription factors that cause hormone deficiencies when mis-expressed. This review will summarize recent findings that led to the first complete clinical description of inherited, isolated corticotropin (ACTH) deficiency (IAD) and to the first molecular mechanism for excessive ACTH production in Cushing's disease. Indeed, mutations in TPIT, a positive or negative regulator of cell fates for different pituitary lineages, cause neonatal IAD, a condition considered anecdotic before discovery of this transcription factor. Cushing's disease is caused by corticotroph adenomas that produce excess ACTH as a result of resistance to glucocorticoids (Gc). Molecular investigation of the normal mechanism of Gc feedback led to identification of two essential proteins for pro-opiomelanocortin repression that are often mis-expressed in corticotroph adenomas thus providing a molecular explanation for Gc resistance. These two proteins, Brg1 and histone deacetylase 2 (HDAC2), are involved in chromatin remodeling and may also participate in the tumorigenic process, as Brg1 is a tumor suppressor. These recent advances have provided improved diagnosis and opened new perspectives for patient management and therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17718852     DOI: 10.1111/j.1399-0004.2007.00877.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  17 in total

1.  Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.

Authors:  Takanori Ebisawa; Katsuyoshi Tojo; Naoko Tajima; Masami Kamio; Yutaka Oki; Katsuhiko Ono; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

2.  Adult pituitary cell maintenance: lineage-specific contribution of self-duplication.

Authors:  David Langlais; Catherine Couture; Marie Kmita; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2013-06-10

3.  Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.

Authors:  Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

4.  Modeling the Sex Differences and Interindividual Variability in the Activity of the Hypothalamic-Pituitary-Adrenal Axis.

Authors:  Rohit T Rao; Ioannis P Androulakis
Journal:  Endocrinology       Date:  2017-11-01       Impact factor: 4.736

5.  Persistent expression of activated Notch inhibits corticotrope and melanotrope differentiation and results in dysfunction of the HPA axis.

Authors:  Leah B Goldberg; Paven K Aujla; Lori T Raetzman
Journal:  Dev Biol       Date:  2011-07-12       Impact factor: 3.582

6.  Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.

Authors:  Odelia Cooper; Anat Ben-Shlomo; Vivien Bonert; Serguei Bannykh; James Mirocha; Shlomo Melmed
Journal:  Horm Cancer       Date:  2010-04       Impact factor: 3.869

7.  Developmental dependence on NurRE and EboxNeuro for expression of pituitary proopiomelanocortin.

Authors:  Pierre-Luc Lavoie; Lionel Budry; Aurélio Balsalobre; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2008-04-03

8.  The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling.

Authors:  Lionel Budry; Aurélio Balsalobre; Yves Gauthier; Konstantin Khetchoumian; Aurore L'honoré; Sophie Vallette; Thierry Brue; Dominique Figarella-Branger; Björn Meij; Jacques Drouin
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

9.  Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas.

Authors:  Zachary M Bush; Maria-Beatriz S Lopes; Isa M Hussaini; John A Jane; Edward R Laws; Mary Lee Vance
Journal:  Pituitary       Date:  2009-06-13       Impact factor: 4.107

Review 10.  Cushing's disease.

Authors:  Frederic Castinetti; Isabelle Morange; Bernard Conte-Devolx; Thierry Brue
Journal:  Orphanet J Rare Dis       Date:  2012-06-18       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.